Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
TARA Stock Chart & Stats
$5.01
-$0.26(-4.26%)
At close: 4:00 PM EST
$5.01
-$0.26(-4.26%)
Day’s Range― - ―
52-Week Range$2.77 - $7.82
Previous CloseN/A
Volume145.20K
Average Volume (3M)1.06M
Market Cap
$260.22M
Enterprise Value$54.87M
Total Cash (Recent Filing)$132.67M
Total Debt (Recent Filing)$3.66M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Mar 11, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding51,630,737
10 Day Avg. Volume1,127,568
30 Day Avg. Volume1,061,273
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio-3.03
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-623.52
Enterprise Value/Ebitda-0.97
Forecast
1Y Price Target
$24.83Price Target Upside395.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Profile And AdoptabilityA favorable safety profile combined with simple preparation and no cold-chain requirements makes TARA-002 easy for community practices to adopt, supporting uptake amid limited BCG availability.
Pivotal Trial AlignmentFDA alignment permitting a pivotal trial versus physician's choice intravesical chemotherapy with a short-term complete response primary endpoint enables a focused registrational strategy and potential first-mover positioning in BCG‑naïve patients.
Regulatory SupportFDA Breakthrough Therapy and Fast Track designations for TARA-002, along with selection for a CMC development pilot program, reduce regulatory risk and support scaled manufacturing and expedited clinical development.
Bears Say
Clinical Readout DelayA postponed interim readout for the BCG‑unresponsive trial delays clarity on clinical efficacy and increases near-term uncertainty for investors and stakeholders.
Endpoint Relevance And BenchmarkingReliance on surrogate biomarkers and indirect comparators raises concerns among some clinicians about clinical meaningfulness and how TARA-002 will be benchmarked against established standard‑of‑care treatments.
Funding And Cash Runway RiskRising research and development spending and high cash burn amid limited cash resources increase the likelihood of additional financing and heighten execution and dilution risk.
Protara Therapeutics News
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $2.77 and its highest was $7.82 in the past 12 months.
What is Protara Therapeutics’s market cap?
Protara Therapeutics’s market cap is $260.22M.
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 52 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Nov 10, 2025. The company reported -$0.31 earnings per share for the quarter, beating the consensus estimate of -$0.384 by $0.074.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -0.34.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 51,630,737 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.31 in its last earnings report, beating expectations of -$0.384. Following the earnings report the stock price went up 5.594%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Currently, no hedge funds are holding shares in TARA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protara Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.83 (395.61% Upside)
$24.83 (395.61% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 9.5%
Last 30 Days ▲ 9.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.20%
12-Months-Change
Fundamentals
Return on Equity
-49.42%
Trailing 12-Months
Asset Growth
53.72%
Trailing 12-Months
Company Description
Protara Therapeutics
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
TARA Stock 12 Month Forecast
Average Price Target
$24.83
▲(395.61% Upside)
Technical Analysis
Protalix
―
TuHURA Biosciences
―
Skye Bioscience
―
Orchestra BioMed Holdings
―
Zura Bio
―
Ownership Overview
3.07% Insiders
5.05% Mutual Funds
0.60% Other Institutional Investors
85.16% Public Companies and Individual Investors
Options Prices
Currently, No data available
---